Skip to main content

Table 3 Immunological parameters: difference between treatment group (aVQ) and control group by independent t -test and result of the repeated measured analysis of variance (ANOVA, influence of treatment)

From: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study

 

Values at baseline (SD)

Difference between aVQ and control

 

aVQ

Control

t

t

t

t

F

   

baseline

week 8

week 16

week 24

ANOVA

CD 16+/CD 56+

10.5 (4.16)

9.38 (3.61)

−0.816

−0.3458

−0.452

−0.2512

0.2823

CD 19+

21.06 (13.71)

20.25 (8.97)

−0.198

0.2786

0.1885

0.3131

0.0199

TNF-α

2.18 (1.61)

1.6 (0.49)

−1.381

−1.4135

−0.407

−1.6893

2.7911

IL-2

1.04 (0.56)

0.94 (0.44)

−0.58

−1.0269

−1.34

−1.019

2.1181

  1. SD: standard deviation; CD 16+/CD 56+ : lymphocytes with CD 16+/CD 56+ (NK-cells), CD 19+ : lymphocytes with CD 19+, TNF-α: tumor necrosis factor alpha, IL-2: interleukin-2.